Clonal dynamics analyses in the ctDNA from CRC patients further suggested that Kirsten rat sarcoma viral oncogene homolog (KRAS) resistance mutations had been present in small subclones before anti-EGFR therapy initiation [8]. This evidence concerns the gene KRAS and colorectal carcinoma.